153 related articles for article (PubMed ID: 25563851)
1. Molecular testing and personalized treatment of lung cancer.
Sampsonas F; Ryan D; McPhillips D; Breen DP
Curr Mol Pharmacol; 2014; 7(1):22-32. PubMed ID: 25563851
[TBL] [Abstract][Full Text] [Related]
2. Molecular alterations in non-small cell lung carcinomas of the young.
VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z
Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236
[TBL] [Abstract][Full Text] [Related]
3. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
[TBL] [Abstract][Full Text] [Related]
4. [Molecular pathology of lung cancer: key to personalized medicine].
Cheng L; Li Y; Zhang SB; Teng XD
Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):715-20. PubMed ID: 23302321
[No Abstract] [Full Text] [Related]
5. Correlation of cytomorphology and molecular findings in EGFR+, KRAS+, and ALK+ lung carcinomas.
Li Z; Dacic S; Pantanowitz L; Khalbuss WE; Nikiforova MN; Monaco SE
Am J Clin Pathol; 2014 Mar; 141(3):420-8. PubMed ID: 24515771
[TBL] [Abstract][Full Text] [Related]
6. Molecular and clinical analysis of predictive biomarkers in non-small-cell lung cancer.
Passaro A; Palazzo A; Trenta P; Mancini ML; Morano F; Cortesi E
Curr Med Chem; 2012; 19(22):3689-700. PubMed ID: 22680928
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
[TBL] [Abstract][Full Text] [Related]
8. Drug Resistance to EGFR Inhibitors in Lung Cancer.
Tetsu O; Hangauer MJ; Phuchareon J; Eisele DW; McCormick F
Chemotherapy; 2016; 61(5):223-35. PubMed ID: 26910730
[TBL] [Abstract][Full Text] [Related]
9. Management and future directions in non-small cell lung cancer with known activating mutations.
Gerber DE; Gandhi L; Costa DB
Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
[TBL] [Abstract][Full Text] [Related]
10. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
Gainor JF; Shaw AT; Sequist LV; Fu X; Azzoli CG; Piotrowska Z; Huynh TG; Zhao L; Fulton L; Schultz KR; Howe E; Farago AF; Sullivan RJ; Stone JR; Digumarthy S; Moran T; Hata AN; Yagi Y; Yeap BY; Engelman JA; Mino-Kenudson M
Clin Cancer Res; 2016 Sep; 22(18):4585-93. PubMed ID: 27225694
[TBL] [Abstract][Full Text] [Related]
11. Coexistence of EGFR mutation and ALK translocation in NSCLC: literature review and case report of response to gefitinib.
Santelmo C; Ravaioli A; Barzotti E; Papi M; Poggi B; Drudi F; Mangianti M; Salvi M; Crinò L
Lung Cancer; 2013 Aug; 81(2):294-6. PubMed ID: 23683537
[TBL] [Abstract][Full Text] [Related]
12. Genomic alterations in lung adenocarcinoma.
Devarakonda S; Morgensztern D; Govindan R
Lancet Oncol; 2015 Jul; 16(7):e342-51. PubMed ID: 26149886
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
[TBL] [Abstract][Full Text] [Related]
14. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
[TBL] [Abstract][Full Text] [Related]
15. ALK and ROS1 testing on lung cancer cytologic samples: Perspectives.
Pisapia P; Lozano MD; Vigliar E; Bellevicine C; Pepe F; Malapelle U; Troncone G
Cancer Cytopathol; 2017 Nov; 125(11):817-830. PubMed ID: 28743163
[TBL] [Abstract][Full Text] [Related]
16. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
[TBL] [Abstract][Full Text] [Related]
17. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
18. Challenges and Strategies in Precision Medicine for Non-Small-Cell Lung Cancer.
Sacco JJ; Al-Akhrass H; Wilson CM
Curr Pharm Des; 2016; 22(28):4374-85. PubMed ID: 27262325
[TBL] [Abstract][Full Text] [Related]
19. [Molecular diagnosis of lung cancer in association with treatment of choice].
Yatabe Y; Shibata N
Rinsho Byori; 2012 Aug; 60(8):786-95. PubMed ID: 23198539
[TBL] [Abstract][Full Text] [Related]
20. [Driven Gene in Patients with Lung Squamous Cell Carcinoma:
Analysis of Clinicopathologic Characteristics and Prognosis].
Zhang T; Li J
Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):648-652. PubMed ID: 27760592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
